Shopping Cart 0
Cart Subtotal
AED 0

rosetta genomics ltd (rosg) - medical equipment - deals and alliances profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 2753
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Rosetta Genomics Ltd (RGL) is a developer of next generation diagnostic tests for personalized medicine. The company provides testing services such as cancer origin, next-gen, thyroid, lung, prostate, bladder, breast, kidney and specialty tests. It also develops tests for thyroid neoplasia, oncology, kidney rejection, Alzheimer's disease, therapeutics and CMV. The company offers RosettaGX platform on the cutting edge of molecular science and genomic testing technologies, with tests. It operates in Australia, New Zealand, Israel, Singapore, Canada, Greece, India, Saudi Arabia, Qatar, the UAE, Israel and Turkey. RGL is headquartered in Rehovot, Israel.

rosetta genomics ltd (rosg)-medical equipment-deals and alliances profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Rosetta Genomics Ltd, Medical Equipment, Deals By Year, 2012 to YTD 2018 6

Rosetta Genomics Ltd, Medical Equipment Deals By Type, 2012 to YTD 2018 7

Rosetta Genomics Ltd, Medical Equipment, Deals By Region, 2012 to YTD 2018 8

Rosetta Genomics Ltd, Medical Equipment, Deals By Market, 2012 to YTD 2018 9

Rosetta Genomics Ltd, Medical Equipment, Deals Summary, 2012 to YTD 2018 10

Rosetta Genomics Ltd, Medical Equipment, Deal Details 12

Partnerships 12

Rosetta Genomics To Enter Into Licensing Agreement For microRNA Intellectual Property And Technology 12

Rosetta Enters Into Licensing Agreement For Patents Related To Cancer Applications 13

Genoptix Enters into Distribution Agreement with Rosetta Genomics 14

Rosetta Genomics Enters into Distribution Agreement with Cytolog Labs 15

Rosetta Genomics Enters into Co-Promotion Agreement with Precipio Diagnostics 16

Rosetta Genomics Enters into Co-Marketing Agreement with Admera Health 17

Rosetta Genomics Enters into Co-Development Agreement with Institute of Molecular Translational Medicine 18

Rosetta Genomics Enters into Co-Development Agreement with Global Pharma Company 19

Rosetta Genomics Enters into Co-Development Agreement with Moffitt Cancer Center 20

Rosetta Genomics Enters Into Co-Development Agreement With Rabin Medical 21

Rosetta Genomics Expands Distribution Agreement With Genekor 22

Rosetta Genomics Enters Into Agreement With Ramot To Develop Nano-Carrier Delivery System To Treat Cancer 23

Equity Offering 24

Rosetta Genomics Plans to Raise Funds through Public Offering of Shares 24

Rosetta Genomics Raises USD2.7 Million in Public Offering of Units 25

Rosetta Genomics Raises USD0.6 Million in Private Placement of Shares6 27

Rosetta Genomics Raises USD8 Million in Private Placement of Units 28

Rosetta Genomics Raises USD5 Million in Second and Final Tranche of Private Placement of Shares 29

Rosetta Genomics Raises USD5 Million in First Tranche of Private Placement of Shares 30

Rosetta Genomics Files Shelf Registration Statement For Public Offering Of Securities For Up To USD 75 Million 31

Rosetta Genomics Completes Underwriters' Exercise Of Over-Allotment Option For USD 4 Million 32

Rosetta Genomics Completes Private Placement Of Shares For USD 6.6 Million 33

Rosetta Genomics Completes Private Placement Of Shares For USD 2 Million 34

Rosetta Genomics Completes Private Placement Of Shares For USD 1.4 Million 35

Debt Offering 36

Rosetta Genomics Raises USD2 Million in Private Placement of Debentures and Warrants 36

Rosetta Genomics Raises USD1.3 Million in Second Tranche of Private Placement of Debentures and Warrants 37

Rosetta Genomics Raises USD3.2 Million in First Tranche of Private Placement of Debentures 38

Rosetta Genomics Completes Private Placement Of Debentures Due 2013 For USD 1.75 Million 39

Acquisition 40

Genoptix to Acquire Rosetta Genomics for USD9 Million 40

Pragmin Prognosis to Acquire Cynogen from Rosetta Genomics for USD3 Million 42

Rosetta Genomics Acquires CynoGen (PersonalizeDx) from Prelude 43

Rosetta Genomics Ltd-Key Competitors 44

Rosetta Genomics Ltd-Key Employees 45

Rosetta Genomics Ltd-Locations And Subsidiaries 46

Head Office 46

Other Locations & Subsidiaries 46

Recent Developments 47

Strategy And Business Planning 47

Jul 06, 2017: Rosetta Genomics Expands Patent Portfolio in Canada, United States, and China 47

Financial Announcements 48

Oct 10, 2017: Rosetta Genomics Reports 2017 Second Quarter and Six Months Financial Results 48

Mar 30, 2017: Rosetta Genomics Reports 2016 Fourth Quarter and Full Year Financial Results 51

Corporate Communications 53

Apr 10, 2018: Rosetta Announces Resignation of Kenneth Berlin as President and CEO 53

Product News 54

May 01, 2017: Rosetta Genomics Expands Patent Portfolio in Europe and Japan 54

Other Significant Developments 55

Sep 05, 2017: Rosetta Genomics to Reduce Operating and Other Expenses 55

Appendix 56

Methodology 56

About GlobalData 56

Contact Us 56

Disclaimer 56


List Of Figure

List of Figures

Rosetta Genomics Ltd, Medical Equipment, Deals by Type, 2012 to YTD 2018 2

Rosetta Genomics Ltd, Medical Equipment, Deals By Year, 2012 to YTD 2018 2

Rosetta Genomics Ltd, Medical Equipment, Deals By Region, 2012 to YTD 2018 2

Rosetta Genomics Ltd, Medical Equipment, Deals By Market, 2012 to YTD 2018 2

Rosetta Genomics Ltd, Medical Equipment, Deals By Year, 2012 to YTD 2018 6

Rosetta Genomics Ltd, Medical Equipment, Deals by Type, 2012 to YTD 2018 7

Rosetta Genomics Ltd, Medical Equipment, Deals By Region, 2012 to YTD 2018 8

Rosetta Genomics Ltd, Medical Equipment, Deals by Market, 2012 to YTD 2018 9


List Of Table

List of Tables

Rosetta Genomics Ltd, Medical Equipment, Key Facts, 2016 2

Rosetta Genomics Ltd, Medical Equipment, Deals Summary, 2012 to YTD 2018 2

Rosetta Genomics Ltd, Medical Equipment, Deals By Year, 2012 to YTD 2018 6

Rosetta Genomics Ltd, Medical Equipment Deals By Type, 2012 to YTD 2018 7

Rosetta Genomics Ltd, Medical Equipment, Deals By Region, 2012 to YTD 2018 8

Rosetta Genomics Ltd, Deals By Market, 2012 to YTD 2018 9

Rosetta Genomics Ltd, Medical Equipment, Deals Summary, 2012 to YTD 2018 10

Rosetta Genomics To Enter Into Licensing Agreement For microRNA Intellectual Property And Technology 12

Rosetta Enters Into Licensing Agreement For Patents Related To Cancer Applications 13

Genoptix Enters into Distribution Agreement with Rosetta Genomics 14

Rosetta Genomics Enters into Distribution Agreement with Cytolog Labs 15

Rosetta Genomics Enters into Co-Promotion Agreement with Precipio Diagnostics 16

Rosetta Genomics Enters into Co-Marketing Agreement with Admera Health 17

Rosetta Genomics Enters into Co-Development Agreement with Institute of Molecular Translational Medicine 18

Rosetta Genomics Enters into Co-Development Agreement with Global Pharma Company 19

Rosetta Genomics Enters into Co-Development Agreement with Moffitt Cancer Center 20

Rosetta Genomics Enters Into Co-Development Agreement With Rabin Medical 21

Rosetta Genomics Expands Distribution Agreement With Genekor 22

Rosetta Genomics Enters Into Agreement With Ramot To Develop Nano-Carrier Delivery System To Treat Cancer 23

Rosetta Genomics Plans to Raise Funds through Public Offering of Shares 24

Rosetta Genomics Raises USD2.7 Million in Public Offering of Units 25

Rosetta Genomics Raises USD0.6 Million in Private Placement of Shares6 27

Rosetta Genomics Raises USD8 Million in Private Placement of Units 28

Rosetta Genomics Raises USD5 Million in Second and Final Tranche of Private Placement of Shares 29

Rosetta Genomics Raises USD5 Million in First Tranche of Private Placement of Shares 30

Rosetta Genomics Files Shelf Registration Statement For Public Offering Of Securities For Up To USD 75 Million 31

Rosetta Genomics Completes Underwriters' Exercise Of Over-Allotment Option For USD 4 Million 32

Rosetta Genomics Completes Private Placement Of Shares For USD 6.6 Million 33

Rosetta Genomics Completes Private Placement Of Shares For USD 2 Million 34

Rosetta Genomics Completes Private Placement Of Shares For USD 1.4 Million 35

Rosetta Genomics Raises USD2 Million in Private Placement of Debentures and Warrants 36

Rosetta Genomics Raises USD1.3 Million in Second Tranche of Private Placement of Debentures and Warrants 37

Rosetta Genomics Raises USD3.2 Million in First Tranche of Private Placement of Debentures 38

Rosetta Genomics Completes Private Placement Of Debentures Due 2013 For USD 1.75 Million 39

Genoptix to Acquire Rosetta Genomics for USD9 Million 40

Pragmin Prognosis to Acquire Cynogen from Rosetta Genomics for USD3 Million 42

Rosetta Genomics Acquires CynoGen (PersonalizeDx) from Prelude 43

Rosetta Genomics Ltd, Key Competitors 44

Rosetta Genomics Ltd, Key Employees 45

Rosetta Genomics Ltd, Other Locations 46

Rosetta Genomics Ltd, Subsidiaries 46

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

rosetta genomics ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Summary

Rosetta Genomics Ltd (RGL) is a developer of next generation diagnostic tests for personalized medicine. The company provides testing services such as cancer origin, next-gen, thyroid, lung, prostate, bladder, breast, kidney and specialty tests. It also develops tests for thyroid neoplasia, oncology, kidney rejection, Alzheimer's disease, therapeutics and CMV. The company offers RosettaGX platform on the cutting edge of molecular science and genomic testing technologies, with tests. It operates in Australia, New Zealand, Israel, Singapore, Canada, Greece, India, Saudi Arabia, Qatar, the UAE, Israel and Turkey. RGL is headquartered in Rehovot, Israel.

rosetta genomics ltd (rosg)-medical equipment-deals and alliances profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Rosetta Genomics Ltd, Medical Equipment, Deals By Year, 2012 to YTD 2018 6

Rosetta Genomics Ltd, Medical Equipment Deals By Type, 2012 to YTD 2018 7

Rosetta Genomics Ltd, Medical Equipment, Deals By Region, 2012 to YTD 2018 8

Rosetta Genomics Ltd, Medical Equipment, Deals By Market, 2012 to YTD 2018 9

Rosetta Genomics Ltd, Medical Equipment, Deals Summary, 2012 to YTD 2018 10

Rosetta Genomics Ltd, Medical Equipment, Deal Details 12

Partnerships 12

Rosetta Genomics To Enter Into Licensing Agreement For microRNA Intellectual Property And Technology 12

Rosetta Enters Into Licensing Agreement For Patents Related To Cancer Applications 13

Genoptix Enters into Distribution Agreement with Rosetta Genomics 14

Rosetta Genomics Enters into Distribution Agreement with Cytolog Labs 15

Rosetta Genomics Enters into Co-Promotion Agreement with Precipio Diagnostics 16

Rosetta Genomics Enters into Co-Marketing Agreement with Admera Health 17

Rosetta Genomics Enters into Co-Development Agreement with Institute of Molecular Translational Medicine 18

Rosetta Genomics Enters into Co-Development Agreement with Global Pharma Company 19

Rosetta Genomics Enters into Co-Development Agreement with Moffitt Cancer Center 20

Rosetta Genomics Enters Into Co-Development Agreement With Rabin Medical 21

Rosetta Genomics Expands Distribution Agreement With Genekor 22

Rosetta Genomics Enters Into Agreement With Ramot To Develop Nano-Carrier Delivery System To Treat Cancer 23

Equity Offering 24

Rosetta Genomics Plans to Raise Funds through Public Offering of Shares 24

Rosetta Genomics Raises USD2.7 Million in Public Offering of Units 25

Rosetta Genomics Raises USD0.6 Million in Private Placement of Shares6 27

Rosetta Genomics Raises USD8 Million in Private Placement of Units 28

Rosetta Genomics Raises USD5 Million in Second and Final Tranche of Private Placement of Shares 29

Rosetta Genomics Raises USD5 Million in First Tranche of Private Placement of Shares 30

Rosetta Genomics Files Shelf Registration Statement For Public Offering Of Securities For Up To USD 75 Million 31

Rosetta Genomics Completes Underwriters' Exercise Of Over-Allotment Option For USD 4 Million 32

Rosetta Genomics Completes Private Placement Of Shares For USD 6.6 Million 33

Rosetta Genomics Completes Private Placement Of Shares For USD 2 Million 34

Rosetta Genomics Completes Private Placement Of Shares For USD 1.4 Million 35

Debt Offering 36

Rosetta Genomics Raises USD2 Million in Private Placement of Debentures and Warrants 36

Rosetta Genomics Raises USD1.3 Million in Second Tranche of Private Placement of Debentures and Warrants 37

Rosetta Genomics Raises USD3.2 Million in First Tranche of Private Placement of Debentures 38

Rosetta Genomics Completes Private Placement Of Debentures Due 2013 For USD 1.75 Million 39

Acquisition 40

Genoptix to Acquire Rosetta Genomics for USD9 Million 40

Pragmin Prognosis to Acquire Cynogen from Rosetta Genomics for USD3 Million 42

Rosetta Genomics Acquires CynoGen (PersonalizeDx) from Prelude 43

Rosetta Genomics Ltd-Key Competitors 44

Rosetta Genomics Ltd-Key Employees 45

Rosetta Genomics Ltd-Locations And Subsidiaries 46

Head Office 46

Other Locations & Subsidiaries 46

Recent Developments 47

Strategy And Business Planning 47

Jul 06, 2017: Rosetta Genomics Expands Patent Portfolio in Canada, United States, and China 47

Financial Announcements 48

Oct 10, 2017: Rosetta Genomics Reports 2017 Second Quarter and Six Months Financial Results 48

Mar 30, 2017: Rosetta Genomics Reports 2016 Fourth Quarter and Full Year Financial Results 51

Corporate Communications 53

Apr 10, 2018: Rosetta Announces Resignation of Kenneth Berlin as President and CEO 53

Product News 54

May 01, 2017: Rosetta Genomics Expands Patent Portfolio in Europe and Japan 54

Other Significant Developments 55

Sep 05, 2017: Rosetta Genomics to Reduce Operating and Other Expenses 55

Appendix 56

Methodology 56

About GlobalData 56

Contact Us 56

Disclaimer 56


List Of Figure

List of Figures

Rosetta Genomics Ltd, Medical Equipment, Deals by Type, 2012 to YTD 2018 2

Rosetta Genomics Ltd, Medical Equipment, Deals By Year, 2012 to YTD 2018 2

Rosetta Genomics Ltd, Medical Equipment, Deals By Region, 2012 to YTD 2018 2

Rosetta Genomics Ltd, Medical Equipment, Deals By Market, 2012 to YTD 2018 2

Rosetta Genomics Ltd, Medical Equipment, Deals By Year, 2012 to YTD 2018 6

Rosetta Genomics Ltd, Medical Equipment, Deals by Type, 2012 to YTD 2018 7

Rosetta Genomics Ltd, Medical Equipment, Deals By Region, 2012 to YTD 2018 8

Rosetta Genomics Ltd, Medical Equipment, Deals by Market, 2012 to YTD 2018 9


List Of Table

List of Tables

Rosetta Genomics Ltd, Medical Equipment, Key Facts, 2016 2

Rosetta Genomics Ltd, Medical Equipment, Deals Summary, 2012 to YTD 2018 2

Rosetta Genomics Ltd, Medical Equipment, Deals By Year, 2012 to YTD 2018 6

Rosetta Genomics Ltd, Medical Equipment Deals By Type, 2012 to YTD 2018 7

Rosetta Genomics Ltd, Medical Equipment, Deals By Region, 2012 to YTD 2018 8

Rosetta Genomics Ltd, Deals By Market, 2012 to YTD 2018 9

Rosetta Genomics Ltd, Medical Equipment, Deals Summary, 2012 to YTD 2018 10

Rosetta Genomics To Enter Into Licensing Agreement For microRNA Intellectual Property And Technology 12

Rosetta Enters Into Licensing Agreement For Patents Related To Cancer Applications 13

Genoptix Enters into Distribution Agreement with Rosetta Genomics 14

Rosetta Genomics Enters into Distribution Agreement with Cytolog Labs 15

Rosetta Genomics Enters into Co-Promotion Agreement with Precipio Diagnostics 16

Rosetta Genomics Enters into Co-Marketing Agreement with Admera Health 17

Rosetta Genomics Enters into Co-Development Agreement with Institute of Molecular Translational Medicine 18

Rosetta Genomics Enters into Co-Development Agreement with Global Pharma Company 19

Rosetta Genomics Enters into Co-Development Agreement with Moffitt Cancer Center 20

Rosetta Genomics Enters Into Co-Development Agreement With Rabin Medical 21

Rosetta Genomics Expands Distribution Agreement With Genekor 22

Rosetta Genomics Enters Into Agreement With Ramot To Develop Nano-Carrier Delivery System To Treat Cancer 23

Rosetta Genomics Plans to Raise Funds through Public Offering of Shares 24

Rosetta Genomics Raises USD2.7 Million in Public Offering of Units 25

Rosetta Genomics Raises USD0.6 Million in Private Placement of Shares6 27

Rosetta Genomics Raises USD8 Million in Private Placement of Units 28

Rosetta Genomics Raises USD5 Million in Second and Final Tranche of Private Placement of Shares 29

Rosetta Genomics Raises USD5 Million in First Tranche of Private Placement of Shares 30

Rosetta Genomics Files Shelf Registration Statement For Public Offering Of Securities For Up To USD 75 Million 31

Rosetta Genomics Completes Underwriters' Exercise Of Over-Allotment Option For USD 4 Million 32

Rosetta Genomics Completes Private Placement Of Shares For USD 6.6 Million 33

Rosetta Genomics Completes Private Placement Of Shares For USD 2 Million 34

Rosetta Genomics Completes Private Placement Of Shares For USD 1.4 Million 35

Rosetta Genomics Raises USD2 Million in Private Placement of Debentures and Warrants 36

Rosetta Genomics Raises USD1.3 Million in Second Tranche of Private Placement of Debentures and Warrants 37

Rosetta Genomics Raises USD3.2 Million in First Tranche of Private Placement of Debentures 38

Rosetta Genomics Completes Private Placement Of Debentures Due 2013 For USD 1.75 Million 39

Genoptix to Acquire Rosetta Genomics for USD9 Million 40

Pragmin Prognosis to Acquire Cynogen from Rosetta Genomics for USD3 Million 42

Rosetta Genomics Acquires CynoGen (PersonalizeDx) from Prelude 43

Rosetta Genomics Ltd, Key Competitors 44

Rosetta Genomics Ltd, Key Employees 45

Rosetta Genomics Ltd, Other Locations 46

Rosetta Genomics Ltd, Subsidiaries 46

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

rosetta genomics ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.